Translational readthrough induction of pathogenic nonsense mutations

European Journal of Medical Genetics

Volumn 49, Issue 6, 2006, Pages 445-450

  Kellermayer, Richard ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Aminoglycosides; NMD; Nonsense mutation; Readthrough; Translation termination

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; GENTAMICIN; NEGAMYCIN; ORPHAN DRUG; PTC 124; TRANSFER RNA; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC DISORDER; HAILEY HAILEY DISEASE; HUMAN; METHODOLOGY; NEPHROTOXICITY; NONHUMAN; NONSENSE MUTATION; OTOTOXICITY; PHARMACOGENETICS; REVIEW; RNA TRANSLATION;

AMINOGLYCOSIDES; CODON, NONSENSE; GENETIC DISEASES, INBORN; HUMANS; MODELS, BIOLOGICAL; PHARMACOGENETICS; PROTEIN BIOSYNTHESIS;

EID: 33845935532     PISSN: 17697212     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmg.2006.04.003     Document Type: Review

References (43)

1. http://www.ptcbio.com/pr012705.html. 1-27-2005. Ref Type: Internet Communication.
2. http://www.ptcbio.com/pr122205.html. 12-22-2005. Ref Type: Internet Communication.
3. 2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells. FASEB J. 18 (2004) 884-886
4. Arakawa M., Shiozuka M., Nakayama Y., Hara T., Hamada M., Kondo S., Ikeda D., Takahashi Y., Sawa R., Nonomura Y., Sheykholeslami K., Kondo K., Kaga K., Kitamura T., Suzuki-Miyagoe Y., Takeda S., and Matsuda R. Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J. Biochem. (Tokyo) 134 (2003) 751-758
5. Burke J.F., and Mogg A.E. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 13 (1985) 6265-6272
6. Carter A.P., Clemons W.M., Brodersen D.E., Morgan-Warren R.J., Wimberly B.T., and Ramakrishnan V. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407 (2000) 340-348
7. Clancy J.P., Bebok Z., Ruiz F., King C., Jones J., Walker L., Greer H., Hong J., Wing L., Macaluso M., Lyrene R., Sorscher E.J., and Bedwell D.M. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 163 (2001) 1683-1692
8. Davies J. W. Gilbert, L. Gorini. Streptomycin, suppression, and the code. Proc. Natl. Acad. Sci. USA 51 (1964) 883-890
9. De Angelis F.G., Sthandier O., Berarducci B., Toso S., Galluzzi G., Ricci E., Cossu G., and Bozzoni I. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc. Natl. Acad. Sci. USA 99 (2002) 9456-9461
10. Denti M.A., Rosa A., D'Antona G., Sthandier O., De Angelis F.G., Nicoletti C., Allocca M., Pansarasa O., Parente V., Musaro A., Auricchio A., Bottinelli R., and Bozzoni I. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc. Natl. Acad. Sci. USA 103 (2006) 3758-3763
11. Dunant P., Walter M.C., Karpati G., and Lochmuller H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 27 (2003) 624-627
12. Fletcher S., Honeyman K., Fall A.M., Harding P.L., Johnsen R.D., and Wilton S.D. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J. Gene Med. 8 (2006) 207-216
13. Friedman S.M., and Weinstein I.B. Lack of fidelity in the translation of synthetic polyribonucleotides. Proc. Natl. Acad. Sci. USA 52 (1964) 988-996
14. Hein L.K., Bawden M., Muller V.J., Sillence D., Hopwood J.J., and Brooks D.A. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J. Mol. Biol. 338 (2004) 453-462
15. Helip-Wooley A., Park M.A., Lemons R.M., and Thoene J.G. Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol. Genet. Metab. 75 (2002) 128-133
16. Holbrook J.A., Neu-Yilik G., Hentze M.W., and Kulozik A.E. Nonsense-mediated decay approaches the clinic. Nat. Genet. 36 (2004) 801-808
17. Howard M., Frizzell R.A., and Bedwell D.M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2 (1996) 467-469
18. Kaufman R.J. Correction of genetic disease by making sense from nonsense. J. Clin. Invest. 104 (1999) 367-368
19. Keeling K.M., and Bedwell D.M. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J. Mol. Med. 80 (2002) 367-376
20. Keeling K.M., Lanier J., Du M., Salas-Marco J., Gao L., Kaenjak-Angeletti A., and Bedwell D.M. Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae. RNA 10 (2004) 691-703
21. Kellermayer R. Hailey-Hailey disease as an orthodisease of PMR1 deficiency in Saccharomyces cerevisiae. FEBS Lett. 579 (2005) 2021-2025
22. Kellermayer R., Szigeti R., Keeling K.M., Bedekovics T., and Bedwell D.M. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey--Hailey disease. J. Invest. Dermatol. 126 (2006) 229-231
23. Kiselev A.V., Ostapenko O.V., Rogozhkina E.V., Kholod N.S., Seit Nebi A.S., Baranov A.N., Lesina E.A., Ivashchenko T.E., Sabetskii V.A., Shavlovskii M.M., Rechinskii V.O., Kiselev L.L., and Baranov V.C. Suppression of nonsense mutations in the Dystrophin gene by a suppressor tRNA gene. Mol. Biol. (Mosk.) 36 (2002) 43-47
24. Kulyte A., Dryselius R., Karlsson J., and Good L. Gene selective suppression of nonsense termination using antisense agents. Biochim. Biophys. Acta 1730 (2005) 165-172
25. Lai C.H., Chun H.H., Nahas S.A., Mitui M., Gamo K.M., Du L., and Gatti R.A. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc. Natl. Acad. Sci. USA 101 (2004) 15676-15681
26. Maire I. Is genotype determination useful in predicting the clinical phenotype in lysosomal storage diseases?. J. Inherit. Metab. Dis. 24 Suppl 2 (2001) 57-61
27. Maldague P., Laurent G., Carlier M.B., and Tulkens P. A 2'guanidyl derivative of gentamicin (S86451) with reduced nephrotoxicity studies at low and medium dose levels in the rat. Arch. Toxicol. Suppl. 7 (1984) 455-458
28. Maquat L.E. Nonsense-mediated mRNA decay in mammals. J. Cell Sci. 118 (2005) 1773-1776
29. Ogle J.M., Carter A.P., and Ramakrishnan V. Insights into the decoding mechanism from recent ribosome structures. Trends Biochem. Sci. 28 (2003) 259-266
30. Palmer E., Wilhelm J.M., and Sherman F. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature 277 (1979) 148-150
31. Parekh-Olmedo H., Ferrara L., Brachman E., and Kmiec E.B. Gene therapy progress and prospects: targeted gene repair. Gene Ther. 12 (2005) 639-646
32. Politano L., Nigro G., Nigro V., Piluso G., Papparella S., Paciello O., and Comi L.I. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 22 (2003) 15-21
33. Porgpermdee S., Yu X., Takagi A., Mayuzumi N., Ogawa H., and Ikeda S. Expression of SPCA1 (Hailey-Hailey disease gene product) in acantholytic dermatoses. J. Dermatol. Sci. 40 (2005) 137-140
34. Roberts R.G., Gardner R.J., and Bobrow M. Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum. Mutat. 4 (1994) 1-11
35. Salas-Marco J., and Bedwell D.M. Discrimination between defects in elongation fidelity and termination efficiency provides mechanistic insights into translational readthrough. J. Mol. Biol. 348 (2005) 801-815
36. Singh A., Ursic D., and Davies J. Phenotypic suppression and misreading Saccharomyces cerevisiae. Nature 277 (1979) 146-148
37. D.E. Sleat, I. Sohar, R.M. Gin, P. Lobel, Aminoglycoside-mediated suppression of nonsense mutations In late infantile neuronal ceroid lipofuscinosis, Eur. J. Paediatr. Neurol. 5 (Suppl A) (2001) 57-62.
38. Temple G.F., Dozy A.M., Roy K.L., and Kan Y.W. Construction of a functional human suppressor tRNA gene: an approach to gene therapy for beta-thalassaemia. Nature 296 (1982) 537-540
39. Usuki F., Yamashita A., Higuchi I., Ohnishi T., Shiraishi T., Osame M., and Ohno S. Inhibition of nonsense-mediated mRNA decay rescues the phenotype in Ullrich's disease. Ann. Neurol. 55 (2004) 740-744
40. Wagner K.R., Hamed S., Hadley D.W., Gropman A.L., Burstein A.H., Escolar D.M., Hoffman E.P., and Fischbeck K.H. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. 49 (2001) 706-711
41. Wilhelm J.M., Jessop J.J., and Pettitt S.E. Aminoglycoside antibiotics and eukaryotic protein synthesis: stimulation of errors in the translation of natural messengers in extracts of cultured human cells. Biochemistry 17 (1978) 1149-1153
42. Wilhelm J.M., Pettitt S.E., and Jessop J.J. Aminoglycoside antibiotics and eukaryotic protein synthesis: structure-function relationships in the stimulation of misreading with a wheat embryo system. Biochemistry 17 (1978) 1143-1149
43. Wilschanski M., Yahav Y., Yaacov Y., Blau H., Bentur L., Rivlin J., Aviram M., Bdolah-Abram T., Bebok Z., Shushi L., Kerem B., and Kerem E. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349 (2003) 1433-1441